Skip to main content
OpenTrials
Completed

NCT Number: NCT06336499

Risk Stratification of Orbital Tumors Based on MRl and Artificial Intelligence

Orbital tumors can be categorized into benign and malignant tumors, and there are significant variations in their biological behavior, treatment, and prognosis. This study aims to enhance the accurate diagnosis and risk stratification of orbital tumors using artificial intelligence (AI) technology and multiparameter magnetic resonance imaging (MRI) data. It further explores the intrinsic relationship between MRI and the differential diagnosis of benign and malignant orbital tumors, as well as the pathological subtypes of malignant tumors and Ki-67 expression levels. This research aims to aid in guiding personalized diagnosis and treatment decision-making for patients with orbital tumors while promoting the practical application and incorporation of AI technology.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

About this study

Although orbital tumors are less common than other eye-related diseases, they can be extremely detrimental to patients. Not only can they cause physical disfigurement, but they can also lead to functional impairments such as diminished vision and restricted eye movement. Orbital tumors can be categorized as either benign or malignant, and there are significant disparities in their biological behavior, treatment approaches, outcomes, and prognosis, which complicates the processes of differential diagnosis and treatment selection. For malignant lesions, the treatment plans and prognosis of patients vary due to the different pathological types and stages. Hence, there is a pressing clinical necessity to devise accurate diagnostic methods for orbital tumors. Multiparametric magnetic resonance imaging (mp-MRI) currently stands as the leading non-invasive imaging technique for diagnosing orbital tumors. This study is centered on precise diagnosis of orbital tumor risk stratification, utilizing artificial intelligence algorithm technology to explore the inherent connection between MRI images and the distinguishing diagnosis of benign and malignant orbital tumors, histological types and Ki-67 expression levels of malignant tumors. It aims to integrate clinical information and quantitative MRI features to construct prediction models, aid in guiding individual diagnosis and treatment decisions for patients with orbital tumors and facilitate the application and advancement of artificial intelligence technology. Specifically, the research objectives are outlined as follows:

  • Establishing a deep learning-based automatic segmentation model for orbital tumors using a multi-sequence MRI dataset from multiple centers, thereby reducing the time required for manual delineation and proving beneficial for subsequent analysis.
  • Developing a model for identifying malignant and benign orbital tumors using multiple machine learning algorithms combined with multi-sequence MRI dataset, with the aim of providing more precise information for distinguishing between these two entities.
  • Constructing robust diagnostic models using machine learning or deep learning approaches with quantitative multi-sequence MRI features to identify the histological type and Ki-67 expression levels of malignant orbital tumors, with the purpose of enhancing detection rates and accuracy, thereby achieving risk stratification for patients with malignant orbital tumors.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The patients with orbital tumors who underwent pre-operative multiparametricMRl (mp-MRl) at Beijing Tongren Hospital from 2015 to 2022.

Exclusion criteria

  • The patients without pre-operative multiparametric MRl (mp-MRl) or clear pathological diagnosis.

Treatment and study plan

Multi-parametric MRI and image analysis by deep learning or machine learning algorithms

Other

Diagnosis models are established using quantitative features extracted from the multi-parametric MRI images and further processed by appropriate deep learning or machine learning algorithms.

Primary outcomes

  1. The area under the curve of Receiver Operating Characteristic of the diagnostic models for the differential diagnosis of malignant and benign orbital tumors, high and low grades of histological types, and levels of Ki-67 expression in malignant ones.

    Time frame: Pre-operation

    The area under the ROC curve is calculated by integrating the ROC curve, which plots Sensitivity against 1 - Specificity.

Secondary outcomes

  1. The area under the Precision-Recall curve of the diagnostic models for the differential diagnosis of malignant and benign orbital tumors, high and low grades of histological types, and high and low levels of Ki-67 expression in malignant orbital tumors.

    Time frame: Pre-operation

    The area under the precision-recall curve is determined by integrating the Precision-Recall curve, which plots Precision against Recall.

  2. Sensitivity of the diagnostic models for the differential diagnosis of malignant and benign orbital tumors, high and low grades of histological types, and high and low levels of Ki-67 expression in malignant orbital tumors.

    Time frame: Pre-operation

    Sensitivity is calculated as the ratio of true positives to the sum of true positives and false negatives.

  3. Specificity of the diagnostic models for the differential diagnosis of malignant and benign orbital tumors, high and low grades of histological types, and high and low levels of Ki-67 expression in malignant orbital tumors.

    Time frame: Pre-operation

    Specificity is calculated as the ratio of true negatives to the sum of true negatives and false positives.

  4. Accuracy of the diagnostic models for the differential diagnosis of malignant and benign orbital tumors, high and low grades of histological types, and high and low levels of Ki-67 expression in malignant orbital tumors.

    Time frame: Pre-operation

    Accuracy is calculated as the ratio of the sum of true positives and true negatives to the total number of cases.

Sponsors and collaborators

Lead sponsor

Beijing Tongren Hospital

Other

Registry information

Important dates

Study start
2012
Primary completion
2022
Study completion
2023
First posted
Mar 28, 2024
Registry last updated
Mar 29, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.